Target selection in drug discovery

Nature Reviews Drug Discovery

Volumn 2, Issue 1, 2003, Pages 63-69

  Knowles, Jonathan ^a   Gromo, Gianni ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATENOLOL; ATORVASTATIN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CAPTOPRIL; CIMETIDINE; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PROPRANOLOL; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB; DRUG RECEPTOR;

BIOTECHNOLOGY; BREAST CANCER; BRONCHOSPASM; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; FINANCIAL MANAGEMENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; DRUG EFFECT; DRUG LEGISLATION; ECONOMICS; HEALTH CARE COST; METHODOLOGY; PHARMACOLOGY;

BIOTECHNOLOGY; DRUG INDUSTRY; HEALTH CARE SECTOR; HUMANS; LEGISLATION, DRUG; PHARMACOLOGY; RECEPTORS, DRUG;

EID: 0037264608     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd986     Document Type: Review

References (18)

1. Jack, D. in Creating the Right Environment for Drug Discovery (ed. Walker, S. R.) 67-71 (Quay Publishing, Lancaster, 1991).
2. Yasuda, S. U. & Woosley R. L. The clinical value of FDA Class C drugs approved from 1981-1988. Clin. Pharmacol. Ther. 52, 577-582 (1992).
3. Morgan, O. Glaxo mergers: the acid test. Observer (Lond.) (January 23, 2000).
4. Jones, R. H. An approach to pricing of innovative research-based medicine. Pharm. Med. 6, 29-38 (1994).
5. Fitzgerald, J. D. Drug discovery and strategic marketing: the need to improve the connection. Drug Dev. Res. 43, 143-148 (1998).
6. Davis, L. UK biotech news short on quality. Scrips 2784 (2002).
7. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
8. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
9. Drews, J. Drug discovery: a historical perspective. Science 287, 1960-1964 (2000).
10. Armstrong, K. A., Eisen, A. & Webber, B. Assessing the risk of breast cancer. N. Engl. J. Med. 342, 564-571 (2000).
11. Kitano, H. Systems biology: a brief overview. Science 295, 1662-1664 (2002).
12. Black, J. Future perspectives in pharmaceutical research. Pharm. Policy Law. 1, 85-92 (1999).
13. Balthasar, H. U., Boschi, R A. & Menke, M. M. Calling the shots in R & D. Harvard Business Rev. 151-160 (May-June) (1978).
14. Lockett, G., Hetherington, B., Yallup, P., Stratford, M. & Cox, B. Modelling a research portfolio using AHP: a group decision process. R&D Management. 16, 151-160 (1986).
15. Islei, G., Lockett, G., Cox, B. & Stratford, M. A. decision support system using judgemental modelling: a case of R&D in the pharmaceutical industry. IEEE Trans. Eng. Management 38, 202-209 (1991).
16. Phillips, L. D. A theory of requisite decision models. Acta Psychologica 56, 29-48 (1984).
17. Bogyo, M., Verhelst, S., Bellingard-Dubouchaud, V., Toba, S. and Greenbaum, D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 7, 27-38 (2000).
18. The management of pharmacology R&D Scrip Report p17 (PJB Publications, Richmond, 1990).